PEAR-TREE2

Indication: Advanced or metastatic kidney cancer

Location: United Kingdom (see below for sites)

Type: Observational

ClinicalTrials information - in process

Protocol (note that this may not be the current version, and should not be used by sites)

Background:

Kidney cancer is a significant area of unmet need. At the moment, localised kidney cancer can be treated by surgery, but advanced or metastatic cancer is often treated with a combination of drugs, including immunotherapy and targeted drugs.

Although there are a number of different drugs, and combinations of drugs, which can be used, we have no way of predicting who will respond to which drugs. This means that some people receive drugs that they don’t respond to.

Description:

This observational study is recruiting up to 200 patients with advanced or metastatic kidney cancer who are due to start new treatment with immunotherapy or targeted drugs. Patients are expected to attend an additional procedure to remove a small piece of tumour using a core needle biopsy. This tumour will be used for analysis on Pear’s system to determine the likelihood of response to a given treatment regimen. As this is an observational study, the results will not be shared with your oncologist at the time of initial treatment, and you will be treated using the standard of care. The goal of the study is to establish the accuracy of Pear’s test at predicting disease response to help guide future patients to better treatments.

If you are interested in enrolling, please contact your doctor about whether you are eligible.

For more information, contact trials@pearbio.com

Open Sites & Investigators:

We hope to open this trial in early 2024